D.E. Shaw & Co’s Stoke Therapeutics STOK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.63M Buy
49,972
+71
+0.1% +$2.33K ﹤0.01% 3077
2025
Q4
$1.58M Sell
49,901
-2,712
-5% -$81.5K ﹤0.01% 3225
2025
Q3
$1.24M Buy
52,613
+21,917
+71% +$376K ﹤0.01% 3325
2025
Q2
$348K Buy
+30,696
New +$291K ﹤0.01% 3799
2025
Q1
Sell
-28,043
Closed -$309K 4727
2024
Q4
$309K Sell
28,043
-143,203
-84% -$1.76M ﹤0.01% 3871
2024
Q3
$2.1M Buy
171,246
+34,236
+25% +$485K ﹤0.01% 2673
2024
Q2
$1.85M Sell
137,010
-56,750
-29% -$766K ﹤0.01% 2719
2024
Q1
$2.62M Buy
193,760
+51,049
+36% +$309K ﹤0.01% 2418
2023
Q4
$751K Sell
142,711
-62,455
-30% -$267K ﹤0.01% 3318
2023
Q3
$808K Buy
205,166
+88,701
+76% +$583K ﹤0.01% 3181
2023
Q2
$1.24M Buy
116,465
+50,496
+77% +$537K ﹤0.01% 2951
2023
Q1
$550K Sell
65,969
-2,866
-4% -$25.9K ﹤0.01% 3513
2022
Q4
$635K Buy
68,835
+42,700
+163% +$444K ﹤0.01% 3723
2022
Q3
$336K Buy
+26,135
New +$416K ﹤0.01% 4250
2022
Q1
Sell
-10,065
Closed -$241K 5920
2021
Q4
$241K Buy
+10,065
New +$240K ﹤0.01% 4789
2021
Q3
Sell
-7,143
Closed -$240K 5219
2021
Q2
$240K Sell
7,143
-4,714
-40% -$167K ﹤0.01% 4384
2021
Q1
$461K Buy
+11,857
New +$675K ﹤0.01% 3542

Other funds holding STOK

D.E. Shaw & Co's STOK Position: Q1 2026 in Review

D.E. Shaw & Co increased its Stoke Therapeutics (STOK) stake by 0.14% in Q1 2026, buying an estimated $2.33K and bringing the position to 49,972 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #3077.

D.E. Shaw & Co first reported a position in STOK in Q1 2021 and has held it in 17 quarters since. The position peaked at $2.62M in Q1 2024. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • D.E. Shaw & Co held 49,972 shares of Stoke Therapeutics worth $1.63M as of Q1 2026.
  • D.E. Shaw & Co bought 71 Stoke Therapeutics shares in Q1 2026, an estimated $2.33K.
  • Stoke Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3077 holding.
  • D.E. Shaw & Co first reported a position in Stoke Therapeutics in Q1 2021 and has held it in 17 quarters since.
  • D.E. Shaw & Co's Stoke Therapeutics position peaked at $2.62M in Q1 2024.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.